ICON Public Limited Company Peer Comparison
Metric | Value | Ranking | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $15.4 Billion | 5/11 | IQV $35.9B |
MTD $27.5B |
WAT $22.7B |
LH $20.2B |
ICLR $15.4B |
MEDP $10.5B |
QGEN $8.7B |
CRL $7.9B |
SYNH $4.5B |
TWST $2.8B |
NEOG $2.2B |
Gross Margin | 25% | 9/11 | MTD 64% |
WAT 63% |
QGEN 61% |
NEOG 49% |
TWST 45% |
IQV 35% |
CRL 35% |
LH 27% |
ICLR 25% |
SYNH 22% |
MEDP -38% |
Profit Margin | 10% | 6/11 | WAT 22% |
MTD 22% |
QGEN 20% |
MEDP 18% |
IQV 11% |
ICLR 10% |
CRL 7% |
LH 4% |
SYNH 0% |
TWST -41% |
NEOG -100% |
EBITDA margin | 19% | 5/11 | MEDP 118% |
QGEN 35% |
IQV 26% |
MTD 23% |
ICLR 19% |
CRL 12% |
SYNH 8% |
LH 7% |
WAT 6% |
TWST -43% |
NEOG -198% |
Quarterly Revenue | $2.0 Billion | 3/11 | IQV $4.0B |
LH $3.3B |
ICLR $2.0B |
SYNH $1.4B |
CRL $1.0B |
MTD $954.5M |
WAT $740.3M |
MEDP $533.3M |
QGEN $501.9M |
NEOG $231.3M |
TWST $84.7M |
Quarterly Earnings | $197.1 Million | 3/11 | IQV $437.0M |
MTD $211.5M |
ICLR $197.1M |
WAT $161.5M |
LH $143.4M |
QGEN $98.1M |
MEDP $96.5M |
CRL $69.7M |
SYNH $793,000 |
TWST -$34.7M |
NEOG -$456.3M |
Quarterly Free Cash Flow | $370.1 Million | 1/11 | ICLR $370.1M |
MTD $233.2M |
CRL $213.1M |
WAT $179.0M |
MEDP $167.4M |
QGEN $138.0M |
NEOG $78.7M |
SYNH -$51.6M |
LH -$0 |
IQV -$0 |
TWST -$0 |
Trailing 4 Quarters Revenue | $6.2 Billion | 3/11 | IQV $15.4B |
LH $13.0B |
ICLR $6.2B |
SYNH $5.4B |
CRL $4.1B |
MTD $3.8B |
WAT $2.9B |
MEDP $2.1B |
QGEN $2.0B |
NEOG $913.8M |
TWST $313.0M |
Trailing 4 Quarters Earnings | $531.5 Million | 5/11 | IQV $4.0B |
LH $3.3B |
ICLR $2.0B |
SYNH $1.4B |
CRL $1.0B |
MTD $954.5M |
WAT $740.3M |
MEDP $533.3M |
QGEN $501.9M |
NEOG $231.3M |
TWST $84.7M |
Quarterly Earnings Growth | 20% | 5/11 | LH 186% |
MEDP 37% |
QGEN 26% |
TWST 25% |
ICLR 20% |
WAT 20% |
MTD 5% |
IQV -7% |
CRL -20% |
SYNH -99% |
NEOG -12985% |
Annual Earnings Growth | 4% | 5/11 | LH 87% |
MEDP 44% |
CRL 9% |
WAT 6% |
ICLR 4% |
TWST 4% |
IQV 0% |
MTD -6% |
SYNH -67% |
QGEN -71% |
NEOG -46707% |
Quarterly Revenue Growth | -1% | 10/11 | TWST 27% |
LH 10% |
MEDP 8% |
QGEN 5% |
WAT 4% |
IQV 2% |
MTD 1% |
NEOG 1% |
SYNH 0% |
ICLR -1% |
CRL -2% |
Annual Revenue Growth | -23% | 11/11 | TWST 21% |
MEDP 10% |
LH 7% |
IQV 2% |
SYNH 1% |
QGEN 0% |
NEOG 0% |
WAT -1% |
CRL -3% |
MTD -3% |
ICLR -23% |
Cash On Hand | $695.5 Million | 4/11 | IQV $1.7B |
LH $1.5B |
QGEN $973.0M |
ICLR $695.5M |
MEDP $656.9M |
WAT $331.5M |
TWST $226.3M |
CRL $210.2M |
NEOG $140.2M |
SYNH $82.2M |
MTD $71.6M |
Short Term Debt | $29.8 Million | 6/11 | LH $1.2B |
IQV $1.1B |
QGEN $555.3M |
MTD $185.8M |
SYNH $68.3M |
ICLR $29.8M |
WAT $25.3M |
TWST $14.8M |
CRL $3.2M |
NEOG $2.6M |
MEDP -$670.9M |
Long Term Debt | $3.4 Billion | 1/11 | ICLR $3.4B |
SYNH $2.8B |
CRL $2.8B |
MTD $1.9B |
QGEN $1.4B |
NEOG $889.9M |
LH $750.6M |
IQV $173.0M |
MEDP $128.3M |
TWST $70.2M |
WAT $0 |
PE | 28.98 | 5/11 | QGEN 94.02 |
SYNH 62.59 |
WAT 36.42 |
MTD 34.51 |
ICLR 28.98 |
MEDP 28.60 |
LH 27.04 |
IQV 26.15 |
CRL 19.02 |
NEOG -1.00 |
TWST -1.00 |
PS | 2.47 | 6/11 | TWST 8.81 |
WAT 7.81 |
MTD 7.30 |
MEDP 5.05 |
QGEN 4.44 |
ICLR 2.47 |
NEOG 2.36 |
IQV 2.33 |
CRL 1.94 |
LH 1.55 |
SYNH 0.82 |
PB | 1.58 | 8/11 | WAT 14.15 |
MEDP 11.86 |
IQV 5.92 |
TWST 5.83 |
LH 2.50 |
QGEN 2.48 |
CRL 2.06 |
ICLR 1.58 |
SYNH 1.28 |
NEOG 0.81 |
MTD 0.00 |
PC | 22.14 | 5/11 | MTD 383.59 |
WAT 68.41 |
SYNH 54.25 |
CRL 37.47 |
ICLR 22.14 |
IQV 21.10 |
MEDP 15.92 |
NEOG 15.39 |
LH 13.28 |
TWST 12.18 |
QGEN 8.98 |
Liabilities to Equity | 0.76 | 9/11 | IQV 3.43 |
WAT 1.81 |
MEDP 1.36 |
SYNH 1.31 |
LH 1.28 |
CRL 1.10 |
MTD 1.05 |
QGEN 0.78 |
ICLR 0.76 |
NEOG 0.52 |
TWST 0.30 |
ROA | 0.03 | 7/11 | MTD 24% | MEDP 18% | WAT 14% | IQV 5% | CRL 5% | LH 4% | ICLR 3% | SYNH 1% | QGEN 1% | NEOG -12% | TWST -34% |
ROE | 0.05 | 7/11 | MEDP 41% |
WAT 39% |
MTD 24% |
IQV 23% |
CRL 11% |
LH 9% |
ICLR 5% |
QGEN 3% |
SYNH 2% |
NEOG -18% |
TWST -44% |
Current Ratio | 2.31 | 3/11 | TWST 4.34 |
NEOG 2.93 |
ICLR 2.31 |
QGEN 2.29 |
CRL 1.92 |
LH 1.78 |
SYNH 1.76 |
MEDP 1.73 |
WAT 1.55 |
IQV 1.29 |
MTD 0.96 |
Quick Ratio | 0.09 | 7/11 | QGEN 94.02 |
SYNH 62.59 |
WAT 36.42 |
MTD 34.51 |
ICLR 28.98 |
MEDP 28.60 |
LH 27.04 |
IQV 26.15 |
CRL 19.02 |
NEOG -1.00 |
TWST -1.00 |
Long Term Debt to Equity | 0.35 | 5/11 | SYNH} 0.81 |
CRL} 0.73 |
MTD} 0.57 |
QGEN} 0.39 |
ICLR} 0.35 |
NEOG} 0.33 |
MEDP} 0.15 |
TWST} 0.15 |
LH} 0.09 |
IQV} 0.03 |
WAT} 0.00 |
Debt to Equity | 0.35 | 5/11 | SYNH 0.83 |
CRL 0.73 |
MTD 0.63 |
QGEN 0.54 |
ICLR 0.35 |
NEOG 0.33 |
LH 0.24 |
IQV 0.22 |
TWST 0.18 |
MEDP 0.15 |
WAT 0.02 |
Burn Rate | -12.98 | 11/11 | QGEN 10.21 |
LH 8.24 |
TWST 5.50 |
CRL 5.06 |
SYNH 0.64 |
NEOG 0.28 |
MTD -0.80 |
WAT -2.14 |
MEDP -2.54 |
IQV -11.83 |
ICLR -12.98 |
Cash to Cap | 0.05 | 6/11 | QGEN 0.11 |
LH 0.08 |
TWST 0.08 |
MEDP 0.06 |
NEOG 0.06 |
ICLR 0.05 |
IQV 0.05 |
CRL 0.03 |
SYNH 0.02 |
WAT 0.01 |
MTD 0.00 |
CCR | 1.88 | 2/11 | CRL 3.06 |
ICLR 1.88 |
MEDP 1.74 |
QGEN 1.41 |
WAT 1.11 |
MTD 1.10 |
NEOG -0.17 |
SYNH -65.12 |
LH |
IQV |
TWST |
EV to EBITDA | 46.34 | 7/11 | WAT} 534.61 |
MTD} 136.22 |
LH} 95.12 |
CRL} 88.79 |
SYNH} 64.31 |
QGEN} 54.43 |
ICLR} 46.34 |
IQV} 34.72 |
MEDP} 15.84 |
NEOG} -6.36 |
TWST} -72.54 |
EV to Revenue | 2.91 | 7/11 | TWST 8.35 |
MTD 7.83 |
WAT 7.70 |
QGEN 4.93 |
MEDP 4.79 |
NEOG 3.19 |
ICLR 2.91 |
CRL 2.57 |
IQV 2.31 |
LH 1.58 |
SYNH 1.34 |